Celerus Diagnostics competitors

Zippia score 3.6

Competitor Summary. See how Celerus Diagnostics compares to its main competitors:

Gish Biomedical has the most employees (100).

Work at Celerus Diagnostics?

Share your experience

Celerus Diagnostics vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Celerus Diagnostics	2004	3.6	Carpinteria, CA	1	$1.0M	30
Nextremity Solutions	2007	4.0	Warsaw, IN	1	$4.7M	39
Gish Biomedical	1976	3.7	Rancho Santa Margarita, CA	1	$7.5M	100
Swissray International	1984	3.7	Elizabeth, NJ	2	$5.9M	50
TransEngen	2006	3.7	Shelton, CT	1	$1.2M	30
Aralez Pharmaceuticals	1996	4.1	New York, NY	1	$105.9M	100
Genesis Pharmaceutical	-	3.7	Hazel Park, MI	1	$1.5M	50
Phonic Ear A/S	1973	3.6	Petaluma, CA	1	$2.9M	30

Rate how well Celerus Diagnostics differentiates itself from its competitors.

Celerus Diagnostics salaries vs competitors

Compare Celerus Diagnostics salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Celerus Diagnostics	$64,954	$31.23	-

Compare Celerus Diagnostics job title salaries vs competitors

Company	Highest salary	Hourly salary
Celerus Diagnostics	$70,555	$33.92
Aralez Pharmaceuticals	$74,825	$35.97
Genesis Pharmaceutical	$72,824	$35.01
Gish Biomedical	$71,944	$34.59
Swissray International	$70,492	$33.89
Phonic Ear A/S	$70,473	$33.88
Nextremity Solutions	$70,468	$33.88
TransEngen	$69,975	$33.64

Do you work at Celerus Diagnostics?

Does Celerus Diagnostics effectively differentiate itself from competitors?

Celerus Diagnostics jobs

Celerus Diagnostics demographics vs competitors

Compare gender at Celerus Diagnostics vs competitors

Job title	Male	Female
Gish Biomedical	73%	27%
Swissray International	81%	19%
Celerus Diagnostics	-	-

Male

Female

100%

75%

50%

25%

Celerus Diagnostics

Swissray International

Gish Biomedical

25%

50%

75%

100%

Compare race at Celerus Diagnostics vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Gish Biomedical	52%	17%	8%	14%	8%	6.6
Swissray International	57%	15%	14%	4%	9%	6.7

Celerus Diagnostics and similar companies CEOs

CEOBio

Rod K. Mayer

Nextremity Solutions

Mr. Mayer has been in the orthopedic business since 1977. He started his orthopaedic career with DePuy serving 18 years as a union employee, marketing trainee, sales associate, Independent Agent, member of the Sales Advisory Board and Business Development Director of their ProSource Division. His overall history in the orthopaedic industry includes extensive experience in sales, distribution and business development. In the fall of 2002, Mr. Mayer founded DVO, a company that was focused on the development and commercialization of innovative orthopaedic products for the upper extremity market. Mr. Mayer co-led the development, growth and eventual sale of DVO Extremity Solutions LLC to Tornier, Inc. in March of 2007. Over the next two years, Mr. Mayer served as Vice President of Sales Execution and was a member of the Tornier Executive Management team. Most recently, Mr. Mayer co-founded Del Palma Orthopedics, a product development company, where he was named President and CEO in April of 2009 and currently serves as a Director. Mr. Mayer currently resides in Warsaw, Indiana, is happily married to his wife of 22 years and has been blessed with 5 children.

Buck Rogers

TransEngen

Buck Rogers is a Blacksmith at Fort Cedar Forge and is based in Shelton, Connecticut. He has worked as Vice President Business Development at WebMD Health Corp, Executive Vice President at Healthport, and Regional Vice President at MEDICAL MANAGER. Buck studied at ITT Technical Institute between 1985 and 1988.

Adrian Adams

Aralez Pharmaceuticals

Adrian Adams was appointed POZEN’s Chief Executive Offer and elected to its Board of Directors on June 1, 2015. Prior to joining POZEN, Mr. Adams served as Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc. from December 2011 until its acquisition by Endo International plc in January 2015 for $2.6 billion. Under his leadership, Auxilium transformed into a men’s healthcare company and broadened its portfolio from two to twelve through the strategic corporate acquisition of Actient Holding LLC and product in-licensing. Prior to joining Auxilium, Mr. Adams served as Chairman and Chief Executive Officer of Neurologix, Inc., a company focused on development of multiple innovative gene therapy development programs. Before Neurologix,